Argentina 
Asia-pacific 
Austria 
Brazil 
England 
Germany 
Hong Kong 
Malaysia 
Netherlands 
Poland 
Switzerland 
France 
We are proudly sponsoring the 2023 OARSI Conference in Denver to advance osteoarthritis treatment and prevention (past event)
At TRB Chemedica, we are committed to advancing the field of osteoarthritis treatment by researching, developing, manufacturing, and marketing various molecules, such as hyaluronic acid and diacerein, to manage osteoarthritis-induced pain.
As osteoarthritis is one of our areas of focus, we are pleased to announce our sponsorship of this year’s Osteoarthritis Research Society International (OARSI) conference in Denver, which is dedicated to advancing prevention and treatment of osteoarthritis, and thus support their mission.
Discover our new building at our Swiss manufacturing plant
A Fusion of Swiss and Japanese Architecture
The building has both a visually appealing design and several technical benefits. It is well insulated and has been optimized to reduce energy expenditure, making use of a system of microperforated plates that circulate hot or cold fluid depending on the season, resulting in lower consumption no matter the time of year.
Solar Powering Sustainability
Our dedication to environmental sustainability and energy efficiency has been a fundamental part of our company’s values long before the construction of this new building. The solar panels installed on the roof of one of our factory buildings have proven to be highly effective, generating between 15-20% of the electricity used on site, reducing our carbon footprint and demonstrating our commitment to sustainable practices.
Our new building is a testament to our company’s commitment to innovation and sustainability. Discover more about our Swissmedic’s Authorized and GMP Qualified Production Site
TRB Thailand is celebrating another significant milestone this year
– its 30th anniversary! (past event)
TRB Thailand has a long and significant history dating back to 1997, when the company first started with only three employees. Today, TRB Thailand employs over 120 people, making it a key subsidiary of the TRB Group.
To celebrate this momentous occasion, our amazing Thai team put together a fantastic party that was attended by over one hundred staff members. Speeches were given by several TRB leaders during the evening, making it a truly special event for all who attended.
How TRB is proactively addressing the new European Medical Devices Regulation (MDR)
The new European Medical Devices Regulation (MDR) just came into effect, with immediate application for new medical devices, generating an interesting debate. Some players welcome this major change which will align national regulations, and believe it will help to remove from the market several medical devices with limited evidence and quality control.
Others highlight that the lack of enforcement of the directives in the past rather than the gaps in regulations originated a critical situation and therefore the need for a new MDR. Still others argue that some of the new, more restrictive regulations might be detrimental to innovation. For example, the classification of most medical software has shifted to class IIa or higher, thereby putting many start-ups and medical applications under pressure.
Irrespective of any personal opinion with regard to this regulation, the more demanding reviewing processes are meant to ensure safer and more effective solutions to the patient’s health conditions.
As a non-exhaustive list of the key changes impacting our products and dossiers we can quote:
- Risk classification of devices and scope of the Regulations
- Clinical investigations and performance studies
- Obligations and regulatory requirements of economic operators
- Traceability
- Identification
- Labelling and instructions for use
You will be able to find a more comprehensive overview on the changes in the Factsheet for healthcare professionals and health institutions, published by the European Commission.
As a Swiss pharmaceutical company, it is our duty to meet some of the highest quality standards in the world and stay one step ahead. That is why we have taken a proactive stance towards being MDR compliant. Our OSTENIL® Line, focused on rheumatology and tendinopathy, received MDR approval and new registrations for OSTENIL®, OSTENIL® Plus, OSTENIL® Mini and OSTENIL® Tendon from the 1st semester of 2022.
In a similar fashion, although we still have a few years until the deadline to switch our VISMED® ophthalmology line over to MDR, our regulatory departments are working extensively to make sure our products will be ready for conformity assessments as well as seamlessly available on the European market.
To learn more about our products, visit your local website.
We are pleased to participate in World Arthritis Day (past event)
World Arthritis Day, referred to as WAD, aims at increasing disease awareness and knowledge on rheumatological conditions around the world. Current estimates list more than 200 rheumatic and musculoskeletal diseases (RMD), but their burden is largely underestimated by the general population. Consequently, a large proportion of patients are either not diagnosed or wait for extended periods of time before consulting their healthcare professionals.
More than 100.000.000 people worldwide suffer from rheumatological symptoms. These symptoms directly impact the quality of life of the patients and their professional activity. The inability to work reduces individuals’ self-esteem and increases their dependence on social assistance, family and friends.
Medical education has for a long time considered RMDs as second priority conditions, which means that symptoms might go unnoticed, misdiagnosed, or mistreated if people don’t have access to rheumatologists, nurses, physical therapists, or other healthcare professionals specifically trained in the field of RMD. As a result, people living with a rheumatic or musculoskeletal disease often have to face their condition alone and are lacking information on their symptoms, diagnosis and treatment options.
World Arthritis Day is intended to raise awareness on the existence and impact of RMD worldwide. This Day is an opportunity for all communities around the world to come together and speak with one voice to bring the much-needed messages to all audiences.
Over the past 20 years, TRB Chemedica has focused its rheumatological activities on osteoarthritis, the most prevalent joint disorder especially in middle-aged and elderly people.
We are pleased to announce our presence at CPHI CONGRESS 2022 (past event)
Every year, CPHI brings together over 100,000 pharmaceutical industry professionals from around the world in physical and online workshops for the purpose of networking and identifying business opportunities. This year’s event is expected to be one of the busiest yet with over 39,000 expected participants.
If you are planning to attend, do not miss the opportunity to visit our stand #41F52.
Please contact our team for more information or to schedule a meeting onsite.
Celebrating 20 years of healthcare excellence in the United Kingdom!
We are proud to announce the 20th anniversary of TRB UK! Responsible for marketing our rheumatology and ophthalmology product ranges in the UK and Ireland since 2002, TRB UK is an ISO 9001 certified company, an achievement that demonstrates our commitment to patients and healthcare professionals and our dedication to quality.
TRB Argentina has been established 30 years ago, becoming over time one of our largest TRB manufacturing sites and affiliate
TRB Argentina’s pharmaceutical plant manufactures a wide range of therapeutic solutions in rheumatology, pain management, infectious diseases and neurology. All its products meet the international GMP (Good Manufacturing Practices) standards, witnessing the high-quality standards and control processes TRB has been implementing since the foundation.
Nowadays, the facilities of TRB Argentina cover 8,300 sq. mt., dedicated to a comprehensive development of the pharmaceutical activity.
TRB Argentina’s main goal is to improve the quality of life for people. Its constant commitment is to ensure the highest quality of both products and services.
The cutting-edge technology of the manufacturing plants and the related pharmaceutical products control are applied to expanding therapeutic domains, including patients’ daily care.
The production facilities are constantly focused on environmental protection, implementing strict health and safety regulations in the workplace as well as adopting, among others, state-of the art methods for the treatment of liquid effluents.
A strong philosophy and a constant strive for improvement are the core model of TRB Argentina.
We are proud to celebrate the 20th anniversary of our Austrian subsidiary
We are proud to celebrate the 20th anniversary of our Austrian subsidiary. Since 2002, the Vienna-based branch has strived to provide high-quality treatment options based on hyaluronic acid for osteoarthritis and dry eye symptoms. Thus, TRB Chemedica Austria has established itself as a competent partner for doctors, pharmacists, and patients in the fields of rheumatology and ophthalmology.
